Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.
Key features that set our library apart include:
partner
Reaxense
upacc
Q32P41
UPID:
TRM5_HUMAN
Alternative names:
M1G-methyltransferase; tRNA [GM37] methyltransferase; tRNA methyltransferase 5 homolog
Alternative UPACC:
Q32P41; B2RN19; Q9P2F4
Background:
tRNA (guanine(37)-N1)-methyltransferase, also known as M1G-methyltransferase and tRNA methyltransferase 5 homolog, plays a crucial role in mitochondrial tRNA methylation. This enzyme specifically methylates the N1 position of guanosine-37 in various tRNAs, a process vital for the biosynthesis of wybutosine (yW), a modified base adjacent to the anticodon of tRNAs necessary for accurate decoding.
Therapeutic significance:
The protein is implicated in a mitochondrial disorder characterized by peripheral neuropathy, variable spasticity, exercise intolerance, and developmental delay. Understanding the role of tRNA (guanine(37)-N1)-methyltransferase could open doors to potential therapeutic strategies for treating this complex condition.